MRK

Schering-Plough Corporation 10-Q Summary

Business Context and Reporting Period

This filing is a Quarterly Report on Form 10-Q for Schering-Plough Corporation for the period ended September 30, 2007. The company operates in three segments: Prescription Pharmaceuticals, Consumer Health Care, and Animal Health. A primary strategic focus during this period was the preparation for the planned acquisition of Organon BioSciences N.V. for approximately €11.0 billion, expected to close by the end of 2007.

Key Financial Metrics (Nine Months Ended Sept 30, 2007)

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 13% year-over-year, driven by strong performance in Prescription Pharmaceuticals (up 14%) and favorable foreign exchange impacts (3%). Key growth drivers included REMICADE (+32%), NASONEX (+19%), and TEMODAR (+22%).
• Profitability Surge: Net income more than doubled, primarily due to a significant increase in equity income from the Merck/Schering-Plough cholesterol joint venture (VYTORIN/ZETIA) and substantial mark-to-market gains on foreign currency options.
• Unusual Items:
  • Foreign Currency Gains: The company recognized $289 million in mark-to-market gains on foreign currency options purchased to hedge the Organon acquisition. This is a non-operating, non-cash gain included in "Other income, net."
  • Equity Income: Equity income from the cholesterol joint venture increased 40% to $1.483 billion, reflecting strong sales of VYTORIN and ZETIA.
• Expense Increases: Research and Development (R&D) expenses rose 33% to $2.071 billion, driven by increased clinical trial spending and $176 million in upfront licensing payments. SG&A expenses increased 11% due to higher promotional spending.
• Liquidity Transformation: Cash and cash equivalents increased by nearly $10 billion to $12.4 billion, resulting from massive financing activities (debt and equity issuances) to fund the Organon acquisition.

Guidance, Outlook, and Risks

• Acquisition Outlook: Management expects the Organon BioSciences transaction to close by year-end 2007. Financing is secured through existing cash, recent debt issuances (€2.0 billion in Oct 2007), and credit facilities.
• Product Outlook: Sales of VYTORIN and ZETIA are expected to continue growing in Q4 2007 and 2008. R&D expenses are expected to continue growing faster than adjusted net sales due to expanding Phase III clinical trials.
• Key Risks:
  • Regulatory & Legal: Ongoing scrutiny regarding pricing practices (AWP litigation), government investigations (Massachusetts Investigation settlement paid $435 million), and patent challenges (Hatch-Waxman actions for Temodar, ZETIA, Clarinex).
  • Product Dependence: Significant reliance on the cholesterol franchise (VYTORIN/ZETIA) and REMICADE. Competition from generics and new entrants poses a threat.
  • Market Risk: Exposure to foreign currency fluctuations and interest rate changes, partially mitigated by hedging strategies.

Investor Verification Checklist

• Quality of Earnings: Verify the sustainability of net income by excluding the $289 million non-recurring mark-to-market gain on currency options.
• Acquisition Financing: Confirm the closing of the Organon BioSciences acquisition and the final debt/equity structure post-closing.
• Joint Venture Performance: Monitor sales trends of VYTORIN and ZETIA, as equity income from this venture is a critical profit driver not reflected in top-line net sales.
• Legal Contingencies: Review updates on the Massachusetts Investigation settlement, AWP litigation, and patent infringement suits regarding key products.
• R&D Pipeline: Assess the progress of Phase III trials for thrombin receptor antagonist, vicriviroc, and golimumab, given the significant increase in R&D spend.